Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Shusen Zheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1459-8261; OpenAlex author ID A5100654810. Sources: OpenAlex.

Their work

Papers
21 (first author 2, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
34
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 6 papers · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: 1 paper

Papers 21

  1. In vivo vaccine generation with a topical small molecule cocktail to eradicates AML and PDAC Co-author DOI 10.1101/2025.10.19.683274↗
  2. 6:2 Cl-PFESA, a proposed safe alternative for PFOS, diminishes the gemcitabine effectiveness in the treatment of pancreatic cancer. Co-author DOI 10.1016/j.jhazmat.2024.134790↗
  3. PFOS and Its Commercial Alternative, 6:2 Cl-PFESA, Induce Multidrug Resistance in Pancreatic Cancer. Co-author DOI 10.1021/acs.est.4c08669↗
  4. Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer. Co-author DOI 10.1002/advs.202201931↗
  5. Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. Co-author DOI 10.1016/j.heliyon.2022.e12064↗
  6. Feasibility of pancreaticoduodenectomy with synchronous liver metastasectomy for oligometastatic pancreatic ductal adenocarcinoma - A case-control study. Last author DOI 10.1016/j.amsu.2020.11.037↗
  7. Prognostic and Clinicopathological Significance of C-Reactive Protein to Albumin Ratio in Patients With Pancreatic Cancer: A Meta-Analysis. Last author DOI 10.1177/1559325820931290↗
  8. Systematic Analysis of Alternative Splicing Landscape in Pancreatic Adenocarcinoma Reveals Regulatory Network Associated with Tumorigenesis and Immune Response. Last author DOI 10.12659/msm.925733↗
  9. MiR-887-3p Negatively Regulates STARD13 and Promotes Pancreatic Cancer Progression. First author DOI 10.2147/cmar.s260542↗
  10. COL6A1 promotes metastasis and predicts poor prognosis in patients with pancreatic cancer. Last author DOI 10.3892/ijo.2019.4825↗
  11. The role of cancer-associated fibroblast MRC-5 in pancreatic cancer. Co-author DOI 10.7150/jca.19614↗
  12. Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/cam4.993↗
  13. HINT2 triggers mitochondrial Ca2+ influx by regulating the mitochondrial Ca2+ uniporter (MCU) complex and enhances gemcitabine apoptotic effect in pancreatic c… Co-author DOI 10.1016/j.canlet.2017.09.020↗
  14. Inhibitor of Pancreatic Cancer by RHIL1RA-Letter. First author DOI 10.1158/1078-0432.ccr-16-3270↗
  15. Laparoscopic versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a single-center experience. Last author DOI 10.1631/jzus.b1600541↗
  16. Efficacy of transcatheter arterial chemoembolization for liver metastases arising from pancreatic cancer. Last author DOI 10.18632/oncotarget.14642↗
  17. The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.14768↗
  18. Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analys… Co-author DOI 10.1038/srep36944↗
  19. Pancreaticoduodenectomy with portal vein/superior mesenteric vein resection for patients with pancreatic cancer with venous invasion. Last author DOI 10.1016/s1499-3872(15)60400-3↗
  20. Overexpression of β3 Chains of Laminin-332 is Associated With Clinicopathologic Features and Decreased Survival in Patients With Pancreatic Adenocarcinoma. Last author DOI 10.1097/pai.0000000000000115↗
  21. Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c. Last author DOI 10.1186/1756-9966-30-66↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiawei Hong · 3 shared papers, 2022–2024 · strength 0.57
  2. Weilin Wang · 6 shared papers, 2015–2017 · strength 0.40
  3. Linping Cao · 2 shared papers, 2024 · strength 0.39
  4. Rongzhen Xu · 1 shared paper, 2025 · strength 0.30
  5. Donghai Jiang · 2 shared papers, 2019–2022 · strength 0.28
  6. Kwabena Gyabaah Owusu-Ansah · 2 shared papers, 2019–2022 · strength 0.28
  7. Xiaobo Xu · 1 shared paper, 2020 · strength 0.24
  8. Jun Qing Yu · 1 shared paper, 2024 · strength 0.20
  9. Qinfen Xie · 1 shared paper, 2020 · strength 0.19
  10. Wan-Wen Weng · 1 shared paper, 2022 · strength 0.19
  11. Sinan Lu · 2 shared papers, 2016–2017 · strength 0.17
  12. Dongkai Zhou · 3 shared papers, 2015–2017 · strength 0.16
  13. Aibin Zhang · 2 shared papers, 2017 · strength 0.16
  14. Yi Shao · 1 shared paper, 2021 · strength 0.15
  15. Suchen Bian · 1 shared paper, 2022 · strength 0.14
  16. Hangxiang Wang · 1 shared paper, 2022 · strength 0.14
  17. Penghong Song · 1 shared paper, 2022 · strength 0.14
  18. Zequn Li · 1 shared paper, 2022 · strength 0.14
  19. Jiahua Lu · 1 shared paper, 2020 · strength 0.13
  20. Jianying Lou · 1 shared paper, 2020 · strength 0.13
  21. Qi Ling · 2 shared papers, 2011–2017 · strength 0.09
  22. Qiyong Li · 1 shared paper, 2018 · strength 0.09
  23. Songming Ding · 1 shared paper, 2018 · strength 0.09
  24. Lin Zhou · 1 shared paper, 2018 · strength 0.09
  25. Christian Röder · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.